# US 2010/0061967 A1 · Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0061967 A1
- Document ID: US20100061967A1
- Status: Published application
- Kind: A1
- Application number: 12/162,160
- Filed: 2007-01-28
- Published: 2010-03-11
- Earliest claimed: 2006-01-27
- Assignees: Dupont Nutrition Biosciences Aps
- Inventors: Nina Rautonen
- Web page: https://patentgrep.com/patent/US20100061967A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23K 10/18: of live microorganisms
- A23K 50/40: for carnivorous animals, e.g. cats or dogs
- A23K 50/75: for poultry
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A61K 35/745: Bifidobacteria
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and/or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and/or B. lactis.

## Claims

### Claim 1

Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling.

### Claim 2 (depends on 1)

Use according to claim 1 wherein the microorganism and/or a metabolite thereof modulates one or more satiety markers.

### Claim 3 (depends on 2)

Use according to claim 2 wherein the modulation occurs post-prandially.

### Claim 4 (depends on 1)

Use according to claim 1 wherein the microorganism and/or a metabolite thereof modulates one or more of the satiety markers selected from the group consisting of: PYY, CCK, Ghrelin, Leptin, GLP-1, orexins, orexigenic hypothalamic neuropeptide Y, acetic acid, amylin and oxyntomodnlin.

### Claim 5 (depends on 4)

Use according to claim 4 wherein the level of one or more of the following satiety markers is increased in plasma and/or the gut: PYY, CCK, GLP-1, leptin (in peripheral blood), insulin and acetic acid.

### Claim 6 (depends on 4)

Use according to claim 4 wherein the level of one or more of the following satiety markers is decreased: ghrelin, orodns and leptin (in brain).

### Claim 7 (depends on 1)

Use according to claim 1 wherein the support is a pharmaceutically acceptable support or a food product.

### Claim 8 (depends on 1)

Use according to claim 1 wherein the use is a cosmetic use and the support is administered to a non-obese subject.

### Claim 9 (depends on 1)

Use according to claim 1 wherein the support is a medicament.

### Claim 10 (depends on 1)

Use according to claim 1 wherein the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight.

### Claim 11 (depends on 1)

Use according to claim 1 wherein the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a disease caused by obesity.

### Claim 12 (depends on 1)

Use according to claim 1 wherein the microorganism is a probiotic microorganism.

### Claim 13 (depends on 1)

Use according to claim 1 wherein the microorganism is a lactic acid bacterium.

### Claim 14 (depends on 1)

Use according to claim 1 wherein the microorganism is a probiotic lactic acid bacterium.

### Claim 15 (depends on 1)

Use according to claim 1 wherein the microorganism is a strain of Lactobacillus spp.

### Claim 16 (depends on 1)

Use according to claim 1 wherein the microorganism is a strain of Lactobacillus acidophilus.

### Claim 17 (depends on 10)

Use according to claim 10 wherein the microorganism is Lactobacillus acidophilus strain PTA-4797.

### Claim 18 (depends on 1)

Use according to claim 1 wherein the microorganism and/or a metabolite thereof is used in combination with one or more lipids and/or one or more lipid micelles.

### Claim 19 (depends on 1)

Use according to claim 1 wherein the microorganism and/or metabolite thereof is used in combination with a prebiotic.

### Claim 20 (depends on 19)

Use according to claim 19 wherein the prebiotic is one or more of the following: inulin, a transgalacto-oligosaccharide, palantinoseoligosaccharide, soybean oligosaccharide, gentiooligosaccharide, oxylooligomers, nondegradable starch, lactosaccharose, lactulose, lactitol, maltitol, or polydextrose.

### Claim 21

Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for inducing satiety.

### Claim 22

A method of modulating satiety signalling in a subject which method comprises administering to the subject an effective amount of at least one strain of a microorganism and/or a metabolite thereof.

### Claim 23 (depends on 22)

A method according to claim 22 wherein the microorganism and/or a metabolite thereof modulates one or more satiety markers.

### Claim 24 (depends on 22)

A method according to claim 22 wherein the modulation occurs post-prandially.

### Claim 25 (depends on 22)

A method according to claim 22 wherein the microorganism and/or a metabolite thereof modulates one or more of the satiety markers selected from the group consisting of: PYY, CCK, Ghrelin, Leptin, GLP-1, orexins, ormdgenic hypothalamic neuropeptide Y, acetic acid, amylin and oxyntomodulin.

### Claim 26 (depends on 25)

A method according to claim 25 wherein the level of one or more of the following satiety markers is increased in the plasma and/or gut: PYY, CCK, GLP-1, leptin (in peripheral blood), insulin and acetic acid.

### Claim 27 (depends on 25)

A method according to claim 25 wherein the level of one or more of the following satiety markers is decreased: gbrelin, orexins and leptin (in brain).

### Claim 28 (depends on 22)

A method according to claim 22 wherein the microorganism is incorporated into a support.

### Claim 29 (depends on 22)

A method according to claim 22 wherein the support is a pharmaceutically acceptable support or a food product.

### Claim 30 (depends on 22)

A method according to claim 22 wherein the method is a cosmetic method of reducing excess weight in a non-obese subject.

### Claim 31 (depends on 29)

A method according to claim 29 wherein the support is a medicament.

### Claim 32 (depends on 22)

A method according to claim 22 wherein the method is a method of treating and/or preventing excess weight and/or a disease caused by excess weight.

### Claim 33 (depends on 22)

A method according to claim 22 wherein the method is a method of treating and/or preventing obesity and/or a disease caused by obesity.

### Claim 34 (depends on 22)

A method according to claim 22 wherein the microorganism is a probiotic microorganism.

### Claim 35 (depends on 22)

A method according to claim 22 wherein the microorganism is a lactic acid bacterium.

### Claim 36 (depends on 22)

A method according to claim 22 wherein the microorganism is a probiotic lactic acid bacterium.

### Claim 37 (depends on 22)

A method according to claim 22 wherein the microorganism is a strain of Lactobacillus acidophilus.

### Claim 38 (depends on 22)

A method according to claim 22 wherein the microorganism and/or metabolite thereof is administered in combination with a prebiotic.

### Claim 39 (depends on 38)

A method according to claim 38 wherein the prebiotic is one or more of the following inulin, a transgalacto-oligosaccharide, palantinoseoligosaccharide, soybean oligosacchatide, gentiooligosaccharide, oxylooligomers, nondegradable starch, lactosaccharose, lactulose, lactitol, maltitol, or polydextrose.

### Claim 40

A method for selecting a microorganism and/or a metabolite thereof to prepare a support for administration to a subject for inducing satiety and/or treating excess weight, including obesity, wherein the method comprises the steps of:
1) bringing a microorganism and/or a metabolite thereof into contact with at least one epithelial cell,
2) detecting the expression of a satiety marker in at least one epithelial cell.

### Claim at position 41

-42. (canceled)
